CPT code 81243 – FMR1 fragile X CGG repeat analysis

Key takeaways

CPT code 81243 is a Tier 1 molecular pathology code for PCR sizing of FMR1 CGG repeats. The lab bills it under the Clinical Laboratory Fee Schedule.

CPT 81244 characterizes abnormal alleles, including methylation status, and many labs add it only as a reflex after an abnormal or intermediate 81243 result.

Code the indication behind the order, such as F84.0 or an intellectual disability code, because Q99.2 fits only a confirmed diagnosis.

Screening codes like Z13.79 are covered less reliably, and Medicare pays for diagnostic genetic testing, not screening.

Check prior authorization and any lab benefit manager before the sample is drawn, since a missing authorization (CARC 197) is hard to appeal.

CPT code 81243 detects expanded FMR1 alleles

CPT code 81243 reports FMR1 gene analysis to detect abnormal, expanded alleles. In the AMA’s official wording, it covers:

FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles.

In plain terms, the lab counts CGG repeats in the FMR1 gene and reports the allele category. It’s a Tier 1 molecular pathology code, part of the 81105-81383 range of specific gene tests. Tier 2 codes (81400-81408) instead group less common tests by complexity level.

Because 81243 is a lab test, Medicare pays it under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. The performing lab bills it, not the ordering clinician. Still, the ordering provider’s notes decide whether it gets paid. The American Medical Association’s CPT code set overview explains how the code set is maintained.

CGG repeat counts decide the allele category

81243 uses polymerase chain reaction (PCR), usually with capillary electrophoresis, to count CGG repeats in FMR1. That count places each allele in one of four categories.

PCR sizes normal, intermediate, and premutation alleles well. Very large full mutations are harder to size, so labs often confirm them with Southern blot or methylation analysis. Interpretation belongs to a genetic counselor or clinical geneticist. The code covers the lab procedure, not that interpretation.

CPT 81243 vs 81244: Sizing first, characterization second

Both codes cover FMR1 gene analysis, but they answer different questions. 81243 asks whether an allele is expanded. 81244 characterizes an abnormal allele, including its expanded size and methylation status.

Many labs add 81244 only as a reflex when the PCR result is abnormal or intermediate. The chart below shows how that decision follows the repeat count.

When both run on the same date of service, check current NCCI edits and the payer’s policy before adding any modifier. Modifier QW doesn’t apply either way, because FMR1 repeat analysis is a high-complexity test under CLIA.

Related codes: When 81171, 81244, or 81479 fits better

Several neighboring codes cover related but distinct tests. Picking the wrong one gets the claim denied or sent back for correction.

Keep 81479 for an FMR1 method that no specific code describes. Payers price it by hand, so send the test methodology and a comparable code with the claim.

Who qualifies for CPT code 81243 testing

Patients qualify when the record documents an accepted clinical indication before the test is ordered. The indications below are broadly accepted by Medicare and commercial payers. They follow American College of Medical Genetics and Genomics (ACMG) guidance.

• Unexplained intellectual disability or developmental delay: The most common indication. Document the cognitive assessment and the absence of a known cause from earlier workup.
• Autism spectrum disorder (ASD): Testing fits when ASD has no known genetic cause. Published series find fragile X in an estimated 2-6% of people with ASD.
• Family history of fragile X or a premutation: First- or second-degree relatives of a confirmed FMR1 mutation carrier qualify for cascade testing.
• Primary ovarian insufficiency (POI) before age 40: The FMR1 premutation is linked to fragile X-associated primary ovarian insufficiency (FXPOI), and ACMG recommends testing.
• Late-onset ataxia or intention tremor after age 50: Premutation carriers face a higher risk of fragile X-associated tremor/ataxia syndrome (FXTAS). Coverage for this indication varies, so verify it before ordering.

Screening indications, coded Z13.79 (encounter for other screening for genetic and chromosomal anomalies), are covered less reliably. Check the payer’s policy before using a screening code as the primary diagnosis.

ICD-10 codes that support medical necessity for 81243

The diagnosis code drives the coverage decision. Code the indication that prompted the order, at the highest specificity the notes support. Outpatient coding doesn’t code a suspected condition as confirmed, so code the presenting signs instead.

Medicare and payer coverage depend on the indication

Medicare coverage for CPT code 81243 runs through each Medicare Administrative Contractor (MAC). Their Local Coverage Determinations (LCDs) and billing articles set the rules.

Medicare pays for diagnostic genetic testing, not screening, so a documented indication is the minimum. Check your MAC’s LCD and billing articles for the patient’s state before billing.

Commercial payers publish their own medical policies, listing covered indications and exclusions for FMR1 testing. Run an insurance eligibility verification and confirm whether the plan uses a laboratory benefit or the medical benefit. That answer decides which claims address the lab uses.

CPT 81243 reimbursement follows the CLFS, even in hospitals

Medicare pays 81243 at a national rate on the Clinical Laboratory Fee Schedule. CMS posts the CLFS files each year and updates them quarterly. Look up the current rate on the CMS Clinical Laboratory Fee Schedule page before you quote expected payment or budget for write-offs.

Hospital outpatient labs are worth a second look. CMS doesn’t package molecular pathology tests into Outpatient Prospective Payment System (OPPS) payments, so 81243 is still paid from the CLFS there.

Commercial rates depend on each lab’s contract with the plan. As a result, the same test can pay differently at a reference lab and a hospital lab.

How an 81243 claim moves from order to payment

The lab, not the ordering clinician, submits the claim. That split means both sides own part of the paperwork. Here’s the path a clean claim takes.

1. Order with the indication: The ordering provider documents the indication in the record before placing the order. Notes added after a denial rarely win an appeal.
2. Check coverage and prior authorization: Read the payer’s LCD or medical policy. Many commercial plans require prior authorization for molecular pathology codes. Medicare rarely requires it for lab tests, but some Medicare LCDs or commercial plans may. Keep the approval number with the claim file.
3. Pick the diagnosis codes: Pair 81243 with the most specific code the record supports. Keep Z13.79 for cases with no diagnostic indication.
4. Submit the claim: The lab files an 837P electronically or a CMS-1500 on paper. ICD-10 codes go in box 21, the CPT code in box 24D, and the authorization number in box 23.
5. Route it to the right address: If the plan carves out lab testing, send the claim to its laboratory benefit manager. A claim sent to the medical benefit gets redirected or denied.
6. Post the payment or work the denial: Match the remittance to the claim, then correct and resubmit anything that comes back.

Documentation the lab needs on file

The record must show medical necessity at the time of the order. To send a clean claim, keep these on file:

• The ordering provider’s notes naming the specific indication
• Earlier genetic test results showing no other cause was found
• Family history notes when cascade testing is the indication
• A signed Advance Beneficiary Notice (ABN) when a Medicare patient’s coverage is uncertain

Before you submit: A quick checklist

• The indication sits in notes dated before the order.
• The ICD-10 code matches that indication, with a screening code only as a last resort.
• Prior authorization is approved, and its number is on the claim.
• You’ve checked whether a lab benefit manager handles the plan.
• If 81244 also ran, both analyses appear in the lab report.
• An ABN is signed if Medicare coverage is in doubt.

Common denials for CPT code 81243 and how to fix them

Denials on 81243 claims tend to fall into four groups, each with a prevention step and an appeal path. Prevention is the faster route, since genetic testing appeals can take 45-90 days under commercial plans.

A denial management workflow that tracks denials by code and payer shows which plans return the most CO-50s for 81243. You can then attach clinical notes for those payers on every claim. Our guide to medical billing denial codes explains each reason code you’ll see on a remittance.

How claims software keeps 81243 lab claims clean

Many of the errors above start with re-keying. Someone copies the order, diagnosis, and authorization number into a clearinghouse portal, and one field slips.

In Pabau, the practice management platform we build, the claim form is pre-filled from the patient record. The CPT code on the service and the diagnosis codes from the problem list land on the claim. Our claims management software also checks that required fields, such as authorization codes, are complete before you can send.

For US practices, Pabau’s Claim.MD integration submits the 837P electronically and checks eligibility in real time. So you confirm coverage before the sample is drawn, rather than after a denial arrives.

Send cleaner lab claims for CPT 81243

Pabau pre-fills claims from the patient record and, in the US, submits 837P claims through Claim.MD with real-time eligibility checks. That means fewer re-keyed fields on fragile X test claims.

Book a demo

Conclusion

Most fragile X claim denials trace back to three choices made before the sample is drawn. They are when the indication was documented, which ICD-10 code was picked, and whether authorization was in place.

So move the work upstream. Settle the indication, the diagnosis code, and the payer’s authorization rules before the sample leaves the practice. Then adding 81244 after an abnormal result becomes routine paperwork.

Book a demo to see how Pabau pre-fills lab claims and checks eligibility before you submit.

Continue your research

Need to understand how electronic claim submission works end to end? Pabau’s Claim.MD clearinghouse guide explains how 837P files are validated, scrubbed, and sent to payers.

Billing an FMR1 method no specific code describes? CPT 81479 covers unlisted molecular pathology claims and the documentation payers ask for.

Comparing Tier 1 and Tier 2 molecular codes? CPT 81401 shows how a Tier 2 code groups less common genetic tests.

Handling remittances after 81243 claims pay? Electronic remittance advice (ERA) processing covers how 835 files map back to the original claims.

Is the lab enrolled with every payer it bills? How to get credentialed with insurance companies walks through the payer enrollment steps that come before the first claim.

Frequently asked questions